How many drugs treat Postmenopausal osteoporosis?

Drug Landscape tracks 10 marketed treatments for Postmenopausal osteoporosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Postmenopausal osteoporosis?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/postmenopausal-osteoporosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Postmenopausal osteoporosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postmenopausal osteoporosis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Postmenopausal osteoporosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Osteobios	CALCITONIN	Sanofi Aventis Us	Calcitonin [EPC]	calcitonin receptor	2025-01-01
Strontium Oxydatum	STRONTIUM	Q Biomed			2022-01-01
Duavee	BAZEDOXIFENE	Wyeth Pharms Pfizer	Estrogen [EPC]	estrogen receptors (ER) α and β	2013-01-01
Prolia	DENOSUMAB	Amgen	RANK Ligand Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 11	2010-01-01
Fablyn	LASOFOXIFENE	Dr. Friedrich Eberth Arzneimittel GmbH	lasofoxifene	Estrogen receptor	2009-01-01
Boniva	IBANDRONIC ACID	Hoffmann La Roche	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Infuvite Adult	Colecalciferol	Novartis	Vitamin D	Vitamin D3 receptor	2000-01-01
Evista	RALOXIFENE	Eli Lilly	Estrogen Agonist/Antagonist	estrogen receptors	1997-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Postmenopausal osteoporosis
Novartis · 2 drugs in Postmenopausal osteoporosis
Pfizer · 2 drugs in Postmenopausal osteoporosis
Amgen · 2 drugs in Postmenopausal osteoporosis
Children's Hospital Medical Center, Cincinnati · 1 drug in Postmenopausal osteoporosis
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Postmenopausal osteoporosis
Alvogen Korea · 1 drug in Postmenopausal osteoporosis
Esjay Pharma · 1 drug in Postmenopausal osteoporosis
Eli Lilly · 1 drug in Postmenopausal osteoporosis
Fdn Consumer · 1 drug in Postmenopausal osteoporosis
Ferring · 1 drug in Postmenopausal osteoporosis
Dr. Friedrich Eberth Arzneimittel GmbH · 1 drug in Postmenopausal osteoporosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Postmenopausal osteoporosis:

Cite this brief

Drug Landscape (2026). Postmenopausal osteoporosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postmenopausal-osteoporosis. Accessed 2026-06-10.

Postmenopausal osteoporosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing